GlaxoSmithKline and Synta Pharmaceuticals Corp announced positive Phase II clinical data for elesclomol (formerly STA-4783), an investigational agent currently in development for metastatic melanoma. A retrospective analysis showed that stage IV metastatic melanoma patients treated with elesclomol and paclitaxel who had not previously received chemotherapy had a statistically significant improvement in progression-free survival (PFS) compared to patients who received paclitaxel alone.

This post is an original post by ScienceDaily: Skin Care News

Posted: May 24th, 2008 under skin health.
Comments: none